View in EDS HTML Full Text PDF Full Text

Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study.

Saved in:
Bibliographic Details
Title: Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study.
Authors: Bourlon MT; Department of Hemato-Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.; Escuela de Medicina, Universidad Panamericana, Mexico City, Mexico., Galli L; Oncology Unit 2, University Hospital of Pisa, Pisa, Italy., Grande E; Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain., Park SH; Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Melichar B; Department of Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czechia., Schieber TJ; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Westwood, KS, United States., Juan-Fita MJ; Department of Medical Oncology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain., Ürün Y; Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Türkiye., Molina-Cerrillo J; Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain., Alonso-Gordoa T; Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Kucharz J; Department of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Warsaw, Poland., Pérez Calabuig E; Medical Oncology Department, CHU Insular-Materno Infantil, Las Palmas de Gran Canaria, Spain., Conteduca V; Unit of Medical Oncology and Biomolecular Therapy and C.R.E.A.T.E - Center for Research and Innovation Medicine, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, Italy., Taha T; The Institute of Cancer Research, London, United Kingdom.; Royal Marsden NHS Foundation Trust, London, United Kingdom., Rescigno P; Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, United Kingdom., Abu-Sini H; Oncology Institute, Haifa, Israel., Spinelli GP; UOC Oncologia Territoriale Ausl Latina, Aprilia, Italy., Manneh Kopp R; Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia., Salfi A; Oncology Unit 2, University Hospital of Pisa, Pisa, Italy., Bhuva D; Department of Medical Oncology, Army Hospital Research and Referral, New Delhi, India., Valdez-Sandoval P; Department of Hemato-Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Mendez-Bribiesca S; Department of Hemato-Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Fiala O; Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czechia.; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia., Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy., Marques Monteiro FS; Genitourinary Cancer Group, Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Oncology and Hematology Department, Hospital Sírio Libanês, Brasília, Brazil., Bamias A; 2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Ghosn M; Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon., Massari F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy., Ansari J; Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates., Santoni M; Medical Oncology Unit, Macerata Hospital, Macerata, Italy.
Source: Frontiers in oncology [Front Oncol] 2025 Jul 25; Vol. 15, pp. 1605282. Date of Electronic Publication: 2025 Jul 25 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2234-943X
DOI:10.3389/fonc.2025.1605282